Viatris will spend as much as $335 million to settle opioid-related claims against the Canonsburg-based pharmaceutical company. The proposed settlement over nine years would come in the form of ...

Viatris has agreed to pay as much as $335 million to settle claims regarding its sale of opioids. The Pittsburgh pharmaceutical company said Monday it was not admitting wrongdoing, but had agreed ...

Viatris has agreed to a settlement in which it will pay up to $335 million to resolve opioid-related claims to state and local governments, the Pittsburgh-based generics specialist said on Monday ...

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a former Pfizer division. Headquartered in ...

Viatris to pay up to $335 million over nine years to settle opioid claims nationwide. The company has accrued $270 million for potential resolution, noted in its 2024 10-K filing. Markets are ...

BofA lowered the firm’s price target on Viatris (VTRS) to $8 from $10 and keeps an Underperform rating on the shares. The firm, in its preview of Q1 EPS updates for its commercial-stage ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the ...